Finola Moore

Company: CatamaranBio

Job title: Director of Pipeline, Research

Seminars:

Allogeneic Natural Killer Cells Engineered to Express HER2-Directed CAR, Interleukin-15 & TGFβ Dominant Negative Receptor Effectively Control HER2+ Tumors 4:00 pm

• We describe here CAT-179, a novel transposon engineered CAR-NK cell therapy for HER2+ solid tumors • CAT-179 cells express three transgenes: a HER2-directed CAR to effectively eliminate tumor cells, a transforming growth factor  (TGF) dominant negative receptor (DNR) for resistance to TGF-mediated immune suppression in the tumor microenvironment, and interleukin 15 (IL-15) to…Read more

day: Day One